Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | CHKA | P35790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2898718 | 0.81 | CYP1A2 (0.34) | CYP1A2ALDH1A1 | |
| SCHEMBL8672253 | 0.81 | PYCR1 (0.33) | CYP1A2 | |
| SCHEMBL4047345 | 0.79 | ESR1 (0.36) | CYP1A2 | |
| SCHEMBL8588108 | 0.78 | — | — | |
| SCHEMBL11792735 | 0.77 | C5AR1 (0.32) | — | |
| Hydrochloric Acid SCHEMBL7648065 | 0.74 | — | — | |
| SCHEMBL11673812 | 0.74 | CYP1A2 (0.36) | CYP1A2ALDH1A1LMNA | |
| SCHEMBL350461 | 0.72 | TSHR (0.38) | CYP1A2ALDH1A1LMNA | |
| SCHEMBL4222206 | 0.72 | — | — | |
| SCHEMBL3435320 | 0.71 | CHKA (0.36) | CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 984 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49735-E1 | Oxazolidinones as modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-28 | — | — | US | claimed |
| EP-4232040-A1 | COMBINATION THERAPY OF PD-1 AXIS BINDING ANTAGONISTS AND LRRK2 INHITIBORS | F. Hoffmann-La Roche AG (CH) | 2023-08-30 | — | — | EP | claimed |
| US-11369584-B2 | Andrographolide derivatives and method of using the same for treatment or prevention of fibrosis | ZHENGZHOU UNIVERSITY (CN) | 2022-06-28 | — | — | US | claimed |
| WO-2022084210-A1 | COMBINATION THERAPY OF PD-1 AXIS BINDING ANTAGONISTS AND LRRK2 INHITIBORS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-04-28 | — | — | WO | claimed |
| EP-3758706-A2 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | The Regents Of The University Of Colorado (US) | 2021-01-06 | — | — | EP | claimed |
| US-20200405723-A1 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2020-12-31 | — | — | US | claimed |
| EP-3608313-A1 | 15-IDENE-14-DEOXY-11,12-DEHYDROANDROGRAPHOLIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARING ANTI-FIBROSIS DRUGS | Zhengzhou University (CN) | 2020-02-12 | — | — | EP | claimed |
| US-20200030280-A1 | ANDROGRAPHOLIDE DERIVATIVES AND METHOD OF USING THE SAME FOR TREATMENT OR PREVENTION OF FIBROSIS | ZHENGZHOU UNIVERSITY (CN) | 2020-01-30 | — | — | US | claimed |
| CN-106279133-A | Organic second-order nonlinear optical chromophore, synthetic method and application | 中国科学院理化技术研究所 | 2017-01-04 | — | — | CN | claimed |
| US-9074129-B2 | Mechanochromic luminescent difluoroboron beta-diketonates | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-07-07 | — | — | US | claimed |
| US-4251609-A | Isoquinolinedione photoelectrophoretic materials for imaging processes | EASTMAN KODAK COMPANY (US) | 1981-02-17 | — | — | US | claimed |
| EP-0010652-A1 | 4-Chlorooxazoles, method for their preparation and their use in photoconductive coatings in electrophotography and as optical brighteners | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-05-14 | — | — | EP | claimed |
| US-4192677-A | ELECTROGRAPHIC CHARGE TRANSFER COMPOUNDS | RICOH CO., LTD. (JP) | 1980-03-11 | — | — | US | claimed |
| US-4160671-A | ESTER OR AMIDE OF AN O-NAPHTHOQUINONE DIAZIDE SULFONIC ACID, ORGANIC DYE, HALOGEN-CONTAINING DERIVATIVE OF PYRONE OR TRIAZINE | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-07-10 | — | — | US | claimed |
| US-4145215-A | PHOTOCONDUCTIVE PIGMENTS | EASTMAN KODAK COMPANY (US) | 1979-03-20 | — | — | US | claimed |
| US-4061637-A | CNS, CARDIOVASCULAR, ANTIINFLAMMATORY, ADRENOLYTIC, ANTIULCER | ISTITUTO LUSO FARMACO D'ITALIA S.R.L. (IT) | 1977-12-06 | — | — | US | claimed |
| US-3967965-A | HETEROCYCLIC UREAS | FUJI PHOTO FILM CO., LTD. (JA) | 1976-07-06 | — | — | US | claimed |
| US-3944417-A | Process for the electrophotographic production of printing plates | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-03-16 | — | — | US | claimed |
| US-3941829-A | PESTICIDE | CIBA-GEIGY CORPORATION (US) | 1976-03-02 | — | — | US | claimed |
| US-3935250-A | PESTICIDE | CIBA-GEIGY CORPORATION (US) | 1976-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200030280-A1 | ANDROGRAPHOLIDE DERIVATIVES AND METHOD OF USING THE SAME FOR TREATMENT OR PREVENTION OF FIBROSIS | MMP1, CYP27A1, PYGL | CYP1A2 170/4885ALDH1A1 356/4885LMNA 1287/4885 |
| US-20200405723-A1 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | WEE1, WEE2, NME1 | CYP1A2 4168/4885ALDH1A1 3933/4885LMNA 1947/4885 |
| US-11369584-B2 | Andrographolide derivatives and method of using the same for treatment or prevention of fibrosis | MMP1, CYP27A1, PYGL | CYP1A2 170/4885ALDH1A1 356/4885LMNA 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.